The World Federation of Hemophilia (WFH) is pleased to announce the launch of the fifth and final activity in Clinical Advances in Gene Therapy for Hemophilia, an online continuing medical education (CME) program developed in collaboration with the National Hemophilia Foundation, the European Haemophilia Consortium and Medscape Education. The program is designed for clinicians but is available to everyone.
Updates on Clinical Trials of Gene Therapy in Hemophilia
Thierry VandenDreissche, PhD
0.50 CME/ABIM MOC. Released September 25, 2018 and valid for credit through September 26, 2019.
In the Updates on Clinical Trials of Gene Therapy in Hemophilia clinical article, Thierry VandenDreissche (Brussels, Belgium) takes an in-depth look at the advances made during recent early phase gene therapy clinical trials in hemophilia that have paved the way for the pivotal phase 3 studies. The article examines the technical challenges faced by the initial approaches and the distinct solutions advanced for hemophilia A and B. It reviews the key results of the most promising studies to date and looks at the directions current research is taking for each. The questions that follow allow learners to see how much they have understood about on-going gene therapy clinical trials in hemophilia and the clinical data that have emerged from these studies.
The full Gene Therapy CME program is now available on the WFH eLearning Platform. This program of five activities covers a range of fascinating subjects, including the science behind gene therapy for hemophilia, the latest safety and efficacy data from clinical trials and the potential role for gene therapy in addressing the challenges of current treatment options in the developed and the developing world. Clinicians can qualify for CME credits for each activity (valid through May to September 2019), and all learners can obtain a completion certificate, or simply use the program to enhance their knowledge of gene therapy in hemophilia.
Click on the following links to learn more about the other activities in the Clinical Advances in Gene Therapy for Hemophilia program.